Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ZEB1 has intrinsic oncogenic functions that control the epithelial-to-mesenchymal transition (EMT) of cancer cells, impacting tumorigenesis from its earliest stages. By integrating microenvironment signals and being implicated in feedback regulatory loops, ZEB1 appears to be a central switch that determines EMT and metastasis of cancer cells. Here, we found that ZEB1 collaborates with
ELK3
, a ternary complex factor belonging to the ETS family, to repress
E-cadherin
expression. ZEB1 functions as a
transcriptional activator
of
ELK3
. We first identified that
ELK3
and
ZEB1
have a positively correlated expression in breast cancer cells by using multiple databases for correlation analysis. Molecular analysis revealed that ZEB1 functions as a
transcriptional activator
of
ELK3
expression. GST pull-down assay and coimmunoprecipitation analysis of wild-type or domain deletion mutants of ZEB1 and
ELK3
showed that these 2 proteins directly bound each other. Furthermore, we demonstrated that ZEB1 and
ELK3
collaborate to repress the expression of
E-cadherin
, a representative protein that initiates EMT. Our finding suggested that
ELK3
is a novel factor of the ZEB1/E-cadherin axis in triple-negative breast cancer cells. IMPLICATIONS:
ELK3
is a novel factor in the ZEB1/E-cadherin axis and ZEB1 has a dual role in
ELK3
as a
transcriptional activator
and as a collaborator to repress
E-cadherin
expression in triple-negative breast cancer cells.
...
PMID:ZEB1 Collaborates with ELK3 to Repress E-Cadherin Expression in Triple-Negative Breast Cancer Cells. 3151 59
